Natamycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Natamycin: From Antifungal Use (No Taiwan License on File) to Vulvovaginal Candidiasis
One-Sentence Summary
Natamycin (DrugBank DB00826) is a polyene macrolide antifungal with no current market authorization in Taiwan (0 licenses) and no structured mechanism-of-action record on file. The TxGNN model predicts efficacy for Vulvovaginal Candidiasis with a 99.97% score, and this is not a speculative new use — the evidence pack’s own literature (spanning 1959–2025) and 1 completed Phase 3 RCT show this is natamycin’s long-established, historically proven antifungal indication (marketed elsewhere as Pimafucin) that Taiwan simply has not registered.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file — Natamycin has zero approved licenses in Taiwan; internationally it is a classic topical/vaginal antifungal (brand Pimafucin) |
| Predicted New Indication | Vulvovaginal Candidiasis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L2 |
| Taiwan Market Status | Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, no structured mechanism-of-action (DrugBank MOA field) data is available for Natamycin. Based on the pharmacological annotation attached to this candidate’s evidence pack, Natamycin is a polyene macrolide antifungal that binds ergosterol in the fungal cell membrane, disrupting membrane integrity and ion permeability — a well-established, decades-old mechanism against Candida spp., not a novel mechanistic inference.
Because Taiwan has no approved license for Natamycin, there is no local “original indication” to compare against. What the evidence pack actually shows is that vulvovaginal candidiasis is natamycin’s classic clinical use worldwide — the literature contains reports of vaginal natamycin/pimaricin tablets treating candidiasis as far back as 1965, continuing through a 2025 international Phase 3 RCT. In this sense, the TxGNN prediction is best read as confirming and re-surfacing an already-proven indication that Taiwan’s regulatory record simply lacks, rather than identifying genuinely new pharmacology. This lowers scientific risk but does not remove the regulatory and safety-documentation gap described below.
Clinical Trial Evidence
No trial is indexed directly under the “vulvovaginal candidiasis” entry in the evidence pack (predicted_indications[0].evidence.clinical_trials is empty).
Currently no related clinical trials registered under this specific ranked entry.
Note: A directly relevant completed Phase 3 RCT — NCT06411314 (n=218, Natamycin + Lactulose vs. Pimafucin vs. Lactulose vaginal suppositories for vulvovaginal candidiasis) — is indexed in the evidence pack under the closely related “candidiasis” and “vulvovaginitis” entries rather than this exact term, and should be treated as directly supporting evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39979898 | 2025 | RCT | BMC Women’s Health | International RCT of Natamycin 100mg + Lactulose 300mg vaginal suppositories vs. Pimafucin vs. Lactulose alone in adult women with vulvovaginal candidiasis; assessed superiority efficacy and safety |
| 4561566 | 1972 | RCT (comparative) | The Medical Journal of Australia | Comparative trial of amphotericin B vs. natamycin (Pimafucin) pessaries for vaginal candidiasis (abstract unavailable; title indicates head-to-head design) |
| 6760652 | 1982 | Cohort | Acta Obstetricia et Gynecologica Scandinavica | 33 patients treated with natamycin vaginal tablets (10 days); partner cream vs. placebo cream compared — 94% vs. 88% cure rate, not significantly different |
| 41412769 | 2025 | Survey | Ceska a Slovenska farmacie | Survey of 408 women in Lviv, Ukraine; lifetime VVC prevalence 72.6%, most common symptoms were vaginal itching (89.7%) and discharge (71.7%) |
| 18288724 | 2008 | Not yet classified | Journal of Pharmaceutical Sciences | Natamycin–γ-cyclodextrin inclusion complex for vaginal mucoadhesive tablets; improved solubility/stability, MIC₉₀ <0.0313 µg/mL against Candida |
| 11048415 | 1999 | Not yet classified | Ceska Gynekologie | Compared diagnosis/treatment outcomes of chronic vaginal candidiasis: natamycin vs. clotrimazole |
| 6966774 | 1980 | Not yet classified | The New Zealand Medical Journal | 50 women given Pimafucin vaginal tablets for 10 days; 76% cure rate at 2 weeks, maintained at 4 weeks |
| 1082689 | 1975 | Not yet classified | Zentralblatt fur Gynakologie | Oral metronidazole + vaginal natamycin combination for mixed urogenital infections; 96.1% cure for trichomoniasis, 89% for candida |
| 5296471 | 1966 | Not yet classified | Canadian Medical Association Journal | 91 pregnant women with vaginal moniliasis treated with pimaricin; 63% culture-negative cure, 94.3% overall symptomatic benefit |
| 159686 | 1979 | Not yet classified | Aust & NZ J Obstet Gynaecol | Controlled trial (n=120): adding a lytic enzyme (Elase) to natamycin increased effectiveness vs. natamycin alone for monilial vulvovaginitis |
US Market Information
Natamycin currently has no approved license or authorization on file in Taiwan (taiwan_regulatory.total_licenses = 0, licenses = []). There is no registered product, dosage form, or approved indication text available for local review.
Safety Considerations
Please refer to the package insert for safety information.
No structured key warnings, contraindications, or drug interaction data are available in this evidence pack (DDI query returned not_found). Since Natamycin is not currently marketed in Taiwan, no local package insert exists — international manufacturer labeling (e.g., Pimafucin SmPC) should be consulted before any clinical use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication is supported by a 2025 international completed Phase 3 RCT plus decades of consistent historical clinical literature on natamycin’s antifungal efficacy in vulvovaginal candidiasis, giving reasonable scientific confidence (L2). However, TFDA-equivalent safety labeling is a Blocking data gap (DG001) and Natamycin has zero existing Taiwan market authorization, so it cannot yet clear a formal safety pre-screening (S1).
To proceed, the following is needed:
- TFDA package insert / warnings & contraindications (DG001, Blocking — required before any S1 safety pre-screen)
- Structured mechanism-of-action data via DrugBank API (DG002)
- Formal drug-drug interaction screening (current query: not found)
- Confirmation of regulatory pathway for Taiwan registration, given the drug has no existing local license
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.